Insight

Filippo Montemurro: Different dosage forms of hormone agonists in endocrine therapy

Photo of Filippo Montemurro taken from www.irccs.com

Oct 15, 2024, 13:10

Filippo Montemurro: Different dosage forms of hormone agonists in endocrine therapy

Filippo Montemurro, Senior Medical Director at F. Hoffmann La Roche, shared a post on X:

“Different dosage forms of gonadotropin-releasing hormone agonist with endocrine therapy in premenopausal hormone receptor-positive breast cancer. Monthly or three-monthly injections?”

Different dosage forms of gonadotropin-releasing hormone agonist with endocrine therapy in premenopausal hormone receptor-positive breast cancer

Authors: Jinna Lin, Yiye Ouyang, Yudong Li, Liang Jin, Shunying Li, Yujie Liu, Yaping Yang, Qianfeng Shi, Mengdi Zhu, Zijie Cai, Jingru Wang, Nianqiu Liu, Yue Hu, Zongqi Wu, Mengzi Wu, Lok Lam Wong, Xiaoting Jiang, Qi Wang, Wang Yang, Qiang Liu.

breast cancer treatment cancer cancer therapy clinical oncology dosage forms endocrine therapy F. Hoffmann La Roche Filippo Montemurro gonadotropin-releasing hormone healthcare professionals hormone receptor-positive breast cancer Jingru Wang Jinna Lin Liang Jin Lok Lam Wong Medical Research Mengdi Zhu Mengzi Wu Nianqiu Liu OncoDaily Oncology patient care Qi Wang Qianfeng Shi Qiang Liu Shunying Li Wang Yang Xiaoting Jiang Yaping Yang Yiye Ouyang Yudong Li Yue Hu Yujie Liu Zijie Cai Zongqi Wu

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage